Akums Drugs and Pharmaceuticals IPO

Akums Drugs and Pharmaceuticals Limited is the largest India-focused CDMO in terms of revenue, production capacity and clients served during the financial year 2023 (among CDMOs assessed by F&S) (Source: F&S Report). During the financial year 2024, the company had a market share of 30.2% by value in the Indian domestic CDMO market.

As of March 31, 2024, their client base for their CDMO business comprised 1,524 Indian and multinational pharmaceutical and wellness companies, increasing from 1,386 as of March 31, 2022.

The market leader’s client base includes pharmaceutical companies, nutraceutical companies, cosmo-derma companies, wellness companies, e-commerce companies, healthcare providers and central and state government entities.

As of March 31, 2024, the company operates four dedicated R&D units. They have also engaged 406 R&D scientists across their businesses. As of March 31, 2024, they have obtained 1,448 trademarks across various dosage forms and formulations.

Further, as of March 31, 2024, they have procured 927 DCGI approvals and 5 patents (Source: F&S Report). As of the date of this Red Herring Prospectus, they have received approval from FSSAI for 923 formulations.